Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders.

Ahn K, Johnson DS, Cravatt BF.

Expert Opin Drug Discov. 2009 Jul;4(7):763-784.

2.

Small molecule probes that target Abl kinase.

Kalesh KA, Sim DS, Wang J, Liu K, Lin Q, Yao SQ.

Chem Commun (Camb). 2010 Feb 21;46(7):1118-20. doi: 10.1039/b919888a. Epub 2009 Dec 14.

PMID:
20126732
3.

Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo.

Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL, Cravatt BF.

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20270-5. doi: 10.1073/pnas.0909411106. Epub 2009 Nov 16.

4.

Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures.

Mileni M, Garfunkle J, DeMartino JK, Cravatt BF, Boger DL, Stevens RC.

J Am Chem Soc. 2009 Aug 5;131(30):10497-506. doi: 10.1021/ja902694n.

5.

Profiling protein tyrosine phosphatase activity with mechanistic probes.

Krishnamurthy D, Barrios AM.

Curr Opin Chem Biol. 2009 Oct;13(4):375-81. doi: 10.1016/j.cbpa.2009.07.017. Epub 2009 Aug 27. Review.

PMID:
19716756
6.

Small molecule microarray-facilitated screening of affinity-based probes (AfBPs) for gamma-secretase.

Shi H, Liu K, Xu A, Yao SQ.

Chem Commun (Camb). 2009 Sep 7;(33):5030-2. doi: 10.1039/b910611a. Epub 2009 Jul 14.

PMID:
19668839
7.

Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism.

Long JZ, Nomura DK, Cravatt BF.

Chem Biol. 2009 Jul 31;16(7):744-53. doi: 10.1016/j.chembiol.2009.05.009.

8.

A suite of activity-based probes for human cytochrome P450 enzymes.

Wright AT, Song JD, Cravatt BF.

J Am Chem Soc. 2009 Aug 5;131(30):10692-700. doi: 10.1021/ja9037609.

9.

The importance of drug-target residence time.

Zhang R, Monsma F.

Curr Opin Drug Discov Devel. 2009 Jul;12(4):488-96. Review.

PMID:
19562645
10.

A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding.

Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, Nakai D, Okazaki O.

Drug Metab Dispos. 2009 Sep;37(9):1970-7. doi: 10.1124/dmd.109.027797. Epub 2009 Jun 1.

11.

Click chemistry and bioorthogonal reactions: unprecedented selectivity in the labeling of biological molecules.

Best MD.

Biochemistry. 2009 Jul 21;48(28):6571-84. doi: 10.1021/bi9007726. Review.

PMID:
19485420
12.

Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain.

Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, Smith SE, Lazerwith S, Stiff C, Kamtekar S, Bhattacharya K, Zhang Y, Swaney S, Van Becelaere K, Stevens RC, Cravatt BF.

Chem Biol. 2009 Apr 24;16(4):411-20. doi: 10.1016/j.chembiol.2009.02.013.

13.

Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH).

Johnson DS, Ahn K, Kesten S, Lazerwith SE, Song Y, Morris M, Fay L, Gregory T, Stiff C, Dunbar JB Jr, Liimatta M, Beidler D, Smith S, Nomanbhoy TK, Cravatt BF.

Bioorg Med Chem Lett. 2009 May 15;19(10):2865-9. doi: 10.1016/j.bmcl.2009.03.080. Epub 2009 Mar 24.

14.
15.

Ubiquitin C-terminal electrophiles are activity-based probes for identification and mechanistic study of ubiquitin conjugating machinery.

Love KR, Pandya RK, Spooner E, Ploegh HL.

ACS Chem Biol. 2009 Apr 17;4(4):275-87. doi: 10.1021/cb9000348.

16.

Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.

Mukherji D, Spicer J.

Expert Opin Investig Drugs. 2009 Mar;18(3):293-301. doi: 10.1517/13543780902762843 . Review.

PMID:
19243280
17.

Covalent modifiers: an orthogonal approach to drug design.

Potashman MH, Duggan ME.

J Med Chem. 2009 Mar 12;52(5):1231-46. doi: 10.1021/jm8008597. Review. No abstract available.

PMID:
19203292
18.

The role of binding kinetics in therapeutically useful drug action.

Swinney DC.

Curr Opin Drug Discov Devel. 2009 Jan;12(1):31-9.

PMID:
19152211
19.

Immune-mediated adverse drug reactions.

Uetrecht J.

Chem Res Toxicol. 2009 Jan;22(1):24-34. doi: 10.1021/tx800389u. Review.

PMID:
19149477
20.

Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.

Karbarz MJ, Luo L, Chang L, Tham CS, Palmer JA, Wilson SJ, Wennerholm ML, Brown SM, Scott BP, Apodaca RL, Keith JM, Wu J, Breitenbucher JG, Chaplan SR, Webb M.

Anesth Analg. 2009 Jan;108(1):316-29. doi: 10.1213/ane.0b013e31818c7cbd.

PMID:
19095868
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk